Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 01)
Gemfibrozil Tablet
Product Images NDC 63187-772
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 63187-772). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 02)
The text provides a table of "Reduction in CHD Rates" based on baseline lipids in the Helsinki Heart Study. It includes the incidence of events, such as fatal and nonfatal myocardial infarctions plus sudden cardiac deaths per 1000 patients over 5 years, and the difference in rates between the placebo and gemfibrozil groups. However, due to the formatting issues and incomplete data, the interpretation of the findings is difficult.*
Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 03)
The text provides a table showing the cardiac events and all-cause mortality (per 1000 patients) occurring during a 3.5-year open-label follow-up to the Helsinki Heart Study. The table compares six open-label groups designated by the original randomization and by the drug taken during the follow-up period, including those who attended the clinic but took no drug, those who took gemfibrozil tablets, and those who did not attend the clinic during the open-label period.*
Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 04)
This is a table presenting the results of the Helsinki Heart Study regarding cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality over an 8.5 year period. The table shows the event numbers, hazard ratio, and confidence intervals for each category for both the gemfibrozil and placebo groups. The intention-to-treat analysis was used, neglecting open-label treatment switches and exposure to study conditions. The study aimed to investigate fatal and non-fatal myocardial infarctions and sudden cardiac deaths.*
Image (94ab25ac 72da 447a Ae3c 6343a5e46f59 05)
This appears to be a list of possible side effects and symptoms that may occur when taking a medication. The text mentions various conditions ranging from weight loss, cardiac issues, and gastrointestinal problems to neurological issues, renal dysfunction, and skin problems. It also mentions potential hematologic, immunologic, and musculoskeletal problems, and increased laboratory values in liver function tests. This seems to be a side effect or symptom profile for a medication or condition, but the name of the medication is not available.*
63187-772-30 (94ab25ac 72da 447a Ae3c 6343a5e46f59 06)
This is a description of a 60-tablet bottle of Gemfibrozil 600mg manufactured by InvaGen Pharmaceuticals Inc. The tablets are film-coated, capsule-shaped, and biconvex with "I" on the left side and "G" on the right side of the bisector on one side and "225" on the other side. The relabeling was done by Proficient Rx LP in Thousand Oaks, CA. The NDC number is 63187-772-60, and the lot number is #0000 with an expiration date of 0000100. The product ID is RG077260, and the barcode is 00383187772604. The medication is for prescription use only, and it should be kept out of the reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
